Limited downside is seen in Dishman Pharma, says Ambareesh Baliga, Independent Analyst.
first published: Feb 11, 2013 07:26 pm
A collection of the most-viewed Moneycontrol videos.

SOBO to Bandra: Why Only South Mumbai Residents Call Bandra a Downgrade | The Tenant

Live: Nifty registers third straight week of gains, up 2% in November | Closing Bell

Live: Can Nifty continue to step up its move to fresh peaks? | Opening Bell

Live: Sensex, Nifty retreat after mounting on new lifetime highs | Closing Bell
You are already a Moneycontrol Pro user.

